Roivant Sciences Ltd.
$26.08B- Market cap
- $29.96B
- Debt
- +$412.94M
- Cash
- −$4.29B
Capital structure 99% equity / 1% debt · EV / Revenue 3157.76x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · Mkt cap
Decision snapshot: ROIV stock price at premium vs NI $41.48 current versus $0.04 implied using P/S multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at NI's multiple
Implied fair value · at ROIV's multiple
Snapshot Sep 8, 2026, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Pricing power
Operating leverage
Multiple premium
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: ROIV FY 2026 (ended Mar 31, 2026) · NI FY 2025 (ended Dec 31, 2025). Fiscal years are not aligned.
Trendline
15 period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
Market cap plus debt, less cash.
Capital structure 99% equity / 1% debt · EV / Revenue 3157.76x
Capital structure 55% equity / 45% debt · EV / Revenue 5.55x · EV / EBITDA 13.04x
NI carries the larger enterprise value at $36.18B against $26.08B; NI trades on the lower EV / Revenue multiple (5.55x vs 3157.76x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
ROIVANT SCIENCES LTD. · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
NISOURCE INC. · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
0.09x
1.71x
Net debt / EBITDA
Leverage against operating earnings
24.52x
5.80x
Cash and equivalents
Liquid reserves on the balance sheet
$4.29B
$110.10M
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Revolution Medicines, Inc.
ROIV vs RVMD
INCYTE CORP
ROIV vs INCY
Sarepta Therapeutics, Inc.
ROIV vs SRPT
EXELIXIS, INC.
ROIV vs EXEL
VERTEX PHARMACEUTICALS INC / MA
ROIV vs VRTX
CENTERPOINT ENERGY INC
ROIV vs CNP
ATMOS ENERGY CORP
ROIV vs ATO
DOMINION ENERGY, INC
ROIV vs D
SEMPRA
ROIV vs SRE
UGI CORP /PA/
ROIV vs UGI
FIRSTENERGY CORP
ROIV vs FE
$412.94M
$16.19B
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.